SRDAN VERSTOVSEK to Immunologic Factors
This is a "connection" page, showing publications SRDAN VERSTOVSEK has written about Immunologic Factors.
Connection Strength
1.311
-
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Apr; 4(4):e165-e175.
Score: 0.428
-
Breakthroughs in myeloproliferative neoplasms. Hematology. 2012 Apr; 17 Suppl 1:S55-8.
Score: 0.304
-
Experience with oral interferon-alpha in patients with essential thrombocythemia and polycythemia vera. Am J Hematol. 2007 Sep; 82(9):859.
Score: 0.221
-
Experimental therapy in myelofibrosis with myeloid metaplasia. Expert Opin Investig Drugs. 2006 Dec; 15(12):1555-63.
Score: 0.210
-
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3880-9.
Score: 0.068
-
Immunotherapy based approaches in myelofibrosis. Expert Rev Hematol. 2017 10; 10(10):903-914.
Score: 0.028
-
Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. Am J Hematol. 2015 Nov; 90(11):1091-2.
Score: 0.024
-
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20; 27(27):4563-9.
Score: 0.016
-
Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia. Curr Hematol Malig Rep. 2007 Feb; 2(1):25-33.
Score: 0.013